Expedited reviews
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

https://doi.org/10.1016/j.jacc.2005.01.045Get rights and content
Under an Elsevier user license
open archive

Objectives

We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen.

Background

The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease.

Methods

The incubation of washed platelets with naproxen for 5 min before the addition of aspirin reduced the irreversible inhibition of thromboxane (TX)B2production by aspirin. The pharmacodynamic interaction between the two drugs was then investigated in four healthy volunteers who received aspirin (100 mg daily) for 6 days and then the combination of aspirin and naproxen for further 6 days: aspirin 2 h before naproxen (500 mg, twice-daily dosing). After 14 days of washout, naproxen was given 2 h before aspirin for further 6 days.

Results

The inhibition of serum TXB2production (index of platelet cyclooxygenase [COX]-1 activity) and platelet aggregation ex vivo and urinary 11-dehydro-TXB2levels (index of TXB2biosynthesis in vivo) by aspirin alone (99 ± 0.2%, 95 ± 0.6%, and 81 ± 4%, respectively) was not significantly altered by the co-administration of naproxen, given either 2 h after aspirin or in reverse order. In a second study, the concurrent administration of a single dose of aspirin and naproxen did not affect platelet TXB2production and aggregation at 1 h after dosing, when aspirin alone causes maximal inhibitory effect. Moreover, the rapid recovery of platelet COX-1 activity and function supports the occurrence of a pharmacodynamic interaction between naproxen and aspirin.

Conclusions

Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and function. This pharmacodynamic interaction might undermine the sustained inhibition of platelet COX-1 that is necessary for aspirin’s cardioprotective effects.

Abbreviations and acronyms

AA
arachidonic acid
BID
twice-daily dosing
CI
confidence interval
COX
cyclooxygenase
IC50
concentrations required to inhibit 50% of enzyme activity
NANSAIDs
nonaspirin nonsteroidal anti-inflammatory drugs
NSAIDs
nonsteroidal anti-inflammatory drugs
PG
prostaglandin
TX
thromboxane

Cited by (0)

Supported by grants from the Italian Ministry of University and Research (MIUR) to the Center of Excellence on Aging, “G. d’Annunzio” University of Chieti, and to Dr. Patrignani (FIRB).